Søren Johan Brun
Copenhagen, December 2021
“ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion”) announces that the ABNCoV2 vaccine demonstrated a strong boosting effect in the clinical Phase II trial conducted by Bavarian Nordic. “
Read more about the exciting news HERE.
Expres2ion was Gemstone Capital’s first IPO (2016)
